-
公开(公告)号：KR1020130030326A
公开(公告)日：2013-03-26
申请号：KR1020120083374
申请日：2012-07-30
Applicant: 서울대학교산학협력단
CPC classification number: C09K11/06 , A61K49/0021 , A61K49/0052 , A61K49/0054 , C07C49/248 , C07C49/255 , C07H15/203 , C09K2211/1011 , C09K19/3469 , H01L51/0052 , H01L51/0062
Abstract: PURPOSE: A high efficiency fluorescence compound is provided to have high single photon absorption and/or two photon absorption characteristic and to not have cytotoxicity. CONSTITUTION: A high efficiency fluorescence compound is indicated in chemical formula 1. In chemical formula 1, R is substituted or unsubstituted naphthalene, substituted or unsubstituted anthracene or substituted or unsubstituted phenalene; R1 is respectively hydrogen, halogen, C1-C6 linear or branched alkyl, C3-C6 cycloalkyl, C1-C6 linear or branched alkoxy, C2-C6 heterocycloalkyl, or substituted or unsubstituted phenyl; and n is 0, 1, 2, or 3.
Abstract translation: 目的：提供高效荧光化合物以具有高单光子吸收和/或两光子吸收特性，并且不具有细胞毒性。 化学式1中，R为取代或未取代的萘，取代或未取代的蒽或取代或未取代的非那非苯; R1分别是氢，卤素，C1-C6直链或支链烷基，C3-C6环烷基，C1-C6直链或支链烷氧基，C2-C6杂环烷基或取代或未取代的苯基; 并且n为0,1,2或3。
-
公开(公告)号：KR101999899B1
公开(公告)日：2019-07-16
申请号：KR1020170136702
申请日：2017-10-20
Applicant: (주)스파크바이오파마 , 서울대학교산학협력단
IPC: C07D491/147 , A61K31/5025
-
23.发明公开
公开(公告)号：KR1020150108515A
公开(公告)日：2015-09-30
申请号：KR1020140031367
申请日：2014-03-18
Applicant: 서울대학교산학협력단
IPC: C07D239/26 , C07D231/16 , C07D487/04 , C07D471/04
Abstract: 본 발명은 카보하이브리드 기반의 분자 골격에 피리미딘, 피라졸 및 피라졸로피리미딘이 융합된 카보하이브리드 헤테로고리 화합물 라이브러리에 관한 것이다.
Abstract translation: 本发明涉及在基于碳杂基的分子框架上融合的具有嘧啶，吡唑和吡唑并嘧啶的碳杂交杂环化合物文库。
-
公开(公告)号：KR1020140114958A
公开(公告)日：2014-09-30
申请号：KR1020130029283
申请日：2013-03-19
Applicant: 서울대학교산학협력단
IPC: C07D311/00 , A61K9/20 , A61P35/00
Abstract: Provided in the present invention are benzopyran derivatives inhibiting formation of microtubule, a pharmaceutically acceptable salt of the same, and a pharmaceutical composition containing the same as active component for treating cancer. A microtubule is in a state of single body and polymer to be controlled according to a need to control cell division, thus blocks movement between single body and polymer of the microtubule to inhibit cell division. The benzopyran derivatives of the present invention inhibit formation of microtubule to be used for treating cancer and other hyperproliferative diseases.
Abstract translation: 本发明提供了抑制微管形成的苯并吡喃衍生物及其药学上可接受的盐，以及含有与治疗癌症的活性成分相同的药物组合物。 微管处于单体和聚合物的状态，根据需要控制细胞分裂，从而阻止单体和微管聚合物之间的运动，以抑制细胞分裂。 本发明的苯并吡喃衍生物抑制用于治疗癌症和其它过度增生性疾病的微管的形成。
-
公开(公告)号：KR101294993B1
公开(公告)日：2013-08-13
申请号：KR1020120083374
申请日：2012-07-30
Applicant: 서울대학교산학협력단
CPC classification number: C09K11/06 , A61K49/0021 , A61K49/0052 , A61K49/0054 , C07C49/248 , C07C49/255 , C07H15/203 , C09K2211/1011
Abstract: 본 발명은 하기 화학식 1로 표시되는 형광 화합물과 이의 제조 방법에 관한 것이다:
[화학식 1]
[상기 식에서,
R은 치환 또는 비치환된 나프탈렌( ), 치환 또는 비치환된 안트라센( ) 또는 치환 또는 비치환된 페날렌( )이고,
여기서, 상기 나프탈렌, 안트라센 또는 페날렌는 각각 독립적으로 수소원자; 히드록시; 할로겐; C1-C10의 직쇄 또는 분지쇄인 알킬; C3-C6의 시클로알킬; C1-C6의 직쇄 또는 분지쇄인 알콕시; 헤테로 원자로서 N, O, 또는 S를 포함하는 C2-C6의 헤테로시클로알킬; 할로겐 원자, 아미노기, 니트릴기, 니트로기, C1-C10의 알킬기, C2-C10의 알케닐기, C1-C10의 알콕시기, C3-C6의 시클로알킬기, 헤테로 원자로서 N, O, 또는 S를 포함하는 C2-C6의 헤테로시클로알킬기, C6-C16의 아릴기, 및 헤테로 원자로서 N, O, 또는 S를 포함하는 C5-C15의 헤테로아릴기로 이루어진 군으로부터 선택된 하나 이상의 기로 치환 또는 비치환된 페닐; 할로겐 원자, 아미노기, 니트릴기, 니트로기, C1-C10의 알킬기, C2-C10의 알케닐기, C1-C10의 알콕시기, C3-C6의 시클로알킬기, 헤테로 원자로서 N, O, 또는 S를 포함하는 C2-C6의 헤테로시클로알킬기, C6-C30의 아릴기, 및 헤테로 원자로서 N, O, 또는 S를 포함하는 C5-C30의 헤테로아릴기로 이루어진 군으로부터 선택된 하나 이상의 기로 치환 또는 비치환된 벤질; 벤조일; C1-C10의 알킬아미노; C2-C10의 디알킬아미노; 및 C1-C10의 알콕시로 이루어진 군으로부터 선택된 하나 이상의 치환기로 치환될 수 있고,
R
1 은 각각 독립적으로 수소원자; 할로겐; C1-C6의 직쇄 또는 분지쇄인 알킬; C3-C6의 시클로알킬; C1-C6의 직쇄 또는 분지쇄인 알콕시; 헤테로 원자로서 N, O, 또는 S를 포함하는 C2-C6의 헤테로시클로알킬; 또는 할로겐 원자, 아미노기, 니트릴기, 니트로기, C1-C10의 알킬기, C2-C10의 알케닐기, C1-C10의 알콕시기, C3-C6의 시클로알킬기, 헤테로 원자로서 N, O, 또는 S를 포함하는 C2-C6의 헤테로시클로알킬기, C6-C16의 아릴기, 및 헤테로 원자로서 N, O, 또는 S를 포함하는 C5-C15의 헤테로아릴기로 이루어진 군으로부터 선택된 하나 이상의 기로 치환 또는 비치환된 페닐이고,
n은 0, 1, 2 또는 3이다(여기서, n이 0인 것은 탄소 고리가 연결되지 않은 것을 의미함)].Abstract translation: 本发明提供白藜芦醇6-O-葡萄糖苷[（E）-4-（8-羟基-6 - （（（2S，3R，4S，5S，6R）-3）的水溶性荧光化合物， 4,5-三羟基-6-（羟甲基）四氢-2H-吡喃-2-基）氧基）萘-2-基）丁-3-烯-2-酮]及其衍生物，其具有至少一个 水溶性取代基，以及通过白藜芦醇3-O-葡萄糖苷及其不具有荧光的式3的衍生物的光化学反应制备该水溶性取代基的方法。 所述新型水溶性荧光化合物具有单光子吸收特性和/或双光子吸收特性，无毒性或小毒性，可用于需要水溶性荧光特性的领域（诊断，荧光探针， 体内成像，显示等）。
-
Patent Agency Ranking
公开(公告)号：KR1020130025709A
公开(公告)日：2013-03-12
申请号：KR1020110089198
申请日：2011-09-02
Applicant: 서울대학교산학협력단
IPC: C09K11/06 , G01N21/76 , G01N33/533
Abstract: PURPOSE: A fluorescent compound for lipid droplet selective staining is provided to have high lipid droplet selectivity, to show a pH-independent staining pattern, and to have a quick staining time. CONSTITUTION: A fluorescent compound for lipid droplet selective staining is represented by chemical formula 1. In chemical formula 1, R^1 is selected from a substituted or unsubstituted C1-20 alkyl group and substituted or a unsubstituted polyethylene glycol group; each of R^2, R^3, R^4, R^5, and R^6 is hydrogen or an electron-donating group; at least one of R^2, R^3, R^4, R^5, and R^6 is an electron donating group; two or more groups of R^2, R^3, R^4, R^5, and R^6 can form selective rings which include carbon, nitrogen, oxygen, or sulfur atoms as a medium; and R^7 is a an electron withdrawing group.
Abstract translation: 目的：提供用于脂滴选择性染色的荧光化合物，以具有高脂滴选择性，显示不依赖于pH的染色图案，并具有快速染色时间。 构成：用于脂滴选择性染色的荧光化合物由化学式1表示。在化学式1中，R 1选自取代或未取代的C 1-20烷基和取代或未取代的聚乙二醇基团; R 2，R 3，R 4，R 5和R 6中的每一个是氢或给电子基团; R 2，R 3，R 4，R 5和R 6中的至少一个是给电子基团; 两个或更多个R 2，R 3，R 4，R 5和R 6基团可以形成包括碳，氮，氧或硫原子作为介质的选择性环; R 7是吸电子基团。
-
公开(公告)号：KR101179618B1
公开(公告)日：2012-09-05
申请号：KR1020110042436
申请日：2011-05-04
Applicant: 삼덕통상 주식회사 , (재)부산경제진흥원 , 서울대학교산학협력단
CPC classification number: A43B3/0005 , A61B5/103 , G08C17/02
Abstract: PURPOSE: Shoes for the old are provided to emit light using an LED and to make the feet of a user comfortable by pressing the plantar. CONSTITUTION: Shoes for the old comprise an outsole(10) which is made of an elastic material and an electronic module(24). A cushion space is formed in the outsole. A plurality of cushion protrusions is formed in the cushion space. A middle groove and a front groove are respectively formed in the middle and front of the outsole. A protrusion unit with a cover covering the middle groove and cushion space is formed from the middle groove to the upper part of the cushion space. In the middle groove, the cover is installed. In the middle of the floor of the front groove, a leaf spring is installed.
Abstract translation: 目的：使用LED发光，并通过按压足底使使用者的脚舒适。 构成：旧的鞋包括由弹性材料制成的外底（10）和电子模块（24）。 在外底形成缓冲空间。 在缓冲空间中形成有多个缓冲突起。 在外底的中间和前部分别形成有中间槽和前槽。 具有覆盖中间槽和缓冲空间的盖的突出单元由缓冲空间的中间槽到上部形成。 在中间槽中，安装盖。 在前槽的底部中间安装有一个板簧。
-
公开(公告)号：KR1020120057716A
公开(公告)日：2012-06-07
申请号：KR1020100081896
申请日：2010-08-24
Applicant: 서울대학교산학협력단
IPC: C07D491/048 , A61K31/35 , A61P3/10 , A61P3/00
Abstract: PURPOSE: A pharmaceutical composition containing a compound which activates AMPK is provided to enhance glucose intake in cells and to prevent and treat type 2 diabetes, hypertension, cardiovascular diseases, and obesity. CONSTITUTION: A pharmaceutical composition for preventing and treating diseases needing AMPK(adenosine monophosphoate-activated protein kinase) activation contains 0.1-50 wt% of a compound of chemical formula I as an active ingredient, or pharmaceutically acceptable salt or solvate thereof. The diseases include type 2 diabetes, metabolic syndrome, hypertension, cardiovascular diseases, and obesity.
Abstract translation: 目的：提供一种含有激活AMPK的化合物的药物组合物，以增强细胞中的葡萄糖摄入量，并预防和治疗2型糖尿病，高血压，心血管疾病和肥胖。 构成：用于预防和治疗需要AMPK（单磷酸腺苷活化蛋白激酶）活化的疾病的药物组合物含有0.1-50重量％的化学式I化合物作为活性成分或其药学上可接受的盐或溶剂化物。 这些疾病包括2型糖尿病，代谢综合征，高血压，心血管疾病和肥胖。
-
公开(公告)号：KR101149878B1
公开(公告)日：2012-05-24
申请号：KR1020090104124
申请日：2009-10-30
Applicant: 서울대학교산학협력단
IPC: C07D493/10 , C07D493/02 , A61K31/435 , A61P3/04
CPC classification number: C07D493/10
Abstract: Provided are a novel compound with a spiro chiral carbon backbone, a stereoisomer thereof, an enantiomer thereof, an in vivo hydrolysable precursor thereof, or a pharmaceutically acceptable salt thereof. The novel compound with the spiro chiral carbon backbone has excellent osteoblast differentiation activity, mast cell inhibitoryactivity, and fatty acid synthesis inhibitory activity in the liver. Therefore, the novel compound can be expected to play an innovative role in treatment of osteoporosis, fatty liver, and obesity.
-
30.发明授权
公开(公告)号：KR101134194B1
公开(公告)日：2012-04-09
申请号：KR1020090119049
申请日：2009-12-03
Applicant: 서울대학교산학협력단
IPC: C07D471/02 , C07D487/04
Abstract: PURPOSE: A method for preparing hetero-biaryl pyridine derivative compounds is provided to easily produce the compounds and to suppress tumor cell proliferation. CONSTITUTION: A method for preparing hetero-biaryl pyridine derivative compound of chemical formula 1 comprises a step of reacting a compound of chemical formula 2 with a compound of chemical formula 3 in a polar protic solvent under the presence of acid catalyst. The polar protic solvent is methanol, ethanol, dichloroethane, dimethyl formamide, or mixture thereof. The acid catalyst is AlCl_3, AcOH, formic acid, trifluoroacetic acid(TFA), or HCl.
-
-
-
-
-
-
-
-
-
Search Results
50
records
(took 0.03 seconds)
